6 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceHIV-1-infectionActive, not recruitingPhase 2 / Phase 32026-10-01NCT04150068
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1HIV-1-infectionRecruitingPhase 22026-09-04NCT07645287
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral TherapyBlood-Borne Infections, Genital Diseases, HIV infectious disease, Infections, RNA Virus Infections, Urogenital Diseases, immune system disorder, inborn error of immunity, infectious disease, lentivirus infection, sexually transmitted disease, uterine carcinosarcoma, viral infectious disease, viral sexually transmitted diseaseRecruitingPhase 32026-08-14NCT07682961
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1HIV-1-InfectionActive, not recruitingPhase 32026-05-29NCT06630299
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedHIV-1-InfectionActive, not recruitingPhase 2 / Phase 32026-04-17NCT06544733
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVHIV-1 InfectionActive, not recruitingPhase 22026-02-04NCT05052996